Clareo Health | A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genosco Inc.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy, adult, male or female (of non-childbearing potential only), 18-55 years of age
Male subjects must follow protocol specified contraception guidance
Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing
BMI ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit and body weight of ≥ 50 kg
Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, or vital signs, as deemed by the PI or designee
No ECG findings of clinical significance as judged by the PI or qualified designee
Understands the study procedures in the ICF and be willing and able to comply with the protocol
You may not be if
Is mentally or legally incapacitated or has significant emotional problems
History or presence of clinically significant medical or psychiatric conditions
History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study
Surgical procedure or Administration of a live vaccination within 30 days prior to the first dose of the study drug
History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
History or presence of hepatic impairment
History or presence of significant cardiovascular conditions or risk factors
Subjects with a higher risk of adverse events in the setting of blood pressure decreases
History or presence of hypersensitivity to compounds related to the study drug excipients
Allergy to non-latex band aids, adhesive dressing, or medical tape
Female subjects of childbearing potential or Female subject with a positive pregnancy test or who is lactating
Positive urine drug or serum alcohol results
Positive results at the screening visit for HIV, HBsAg, or HCV, or a clinically significant history of infection within 3 months prior to screening
Inability or unwillingness to avoid use of medications, supplements, or substances that may affect CYP enzymes, drug transporters, blood pressure, or QT/QTc interval within the specified washout periods prior to dosing
Has been on a diet incompatible with the on-study diet, or unable to swallow multiple tablets by mouth
Has donated or lost more than 500 mL of blood within 56 days prior to the first dosing, or Plasma donation within 7 days prior to the first dosing
Subjects with dietary restrictions that would prevent subjects from consuming a high-fat/high-calorie meal
Participation in another clinical study within 30 days or 5 half-lives of the product prior to the first dosing
Any reason determined by the PI or designee, in their opinion, that would prevent the subject's participation in the study
